[{"orgOrder":0,"company":"Laminar Pharma","sponsor":"LabCorp | Northern Institute for Cancer Research (Newcastle) | Theradis pharma | Lipodom Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"LAM561","moa":"||Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laminar Pharma \/ LabCorp | Northern Institute for Cancer Research (Newcastle) | Theradis pharma | Lipodom Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ LabCorp | Northern Institute for Cancer Research (Newcastle) | Theradis pharma | Lipodom Therapeutics"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"||Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laminar Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"||Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laminar Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"||Cholesterol efflux","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laminar Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Laminar Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Laminar Pharma","sponsor":"Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Cholesterol efflux","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Laminar Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laminar Pharma \/ Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Laminar Pharma \/ Hackensack Meridian Health | Dana-Farber Cancer Institute | Laminar Pharma"}]